Remove 2004 Remove Immunity Remove Immunization
article thumbnail

UCB and Biogen’s dapirolizumab pegol paves path for systemic lupus erythematosus treatment

Express Pharma

In PHOENYCS GO, dapirolizumab pegol achieved the primary endpoint of achieving a BILAG 2004-based Composite Lupus Assessment (BICLA) response at Week 48. They will debut as a late-breaking abstract at the upcoming American College of Rheumatology (ACR) 2024 congress, which will take place from November 14 to 19, 2024.

Labelling 105
article thumbnail

Reconfiguring COVID and influenza vaccines for long-term effectiveness

pharmaphorum

When exposed to a virus, one’s immune system develops antibodies in response to foreign antigens, with or without a vaccine. However, a vaccine trains the immune system to recognise that familiar virus and kill it more rapidly. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mesoblast pummelled as Novartis exits COVID deal

pharmaphorum

In COVID-19, the drug was being tested in patients with acute respiratory distress (ARDS), which like GvHD is caused by over-stimulation of inflammatory cytokines, which causes the immune system to attack the patient’s own body. It has made cumulative loses of almost $650 million since being founded in 2004.

Immunity 101
article thumbnail

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

pharmaphorum

Some cancer cells contain large amounts of PD-L1, which helps them to evade the body’s immune system. Lung cancer prevalence rates have risen by 23% since 2004, notes the BLF: “The earlier part of this trend may have been affected by changes in the way data were collated and incentivised.

article thumbnail

Trial bias concern scuppers Y-mAbs brain cancer drug in FDA vote

pharmaphorum

The two groups were also separated by a sizeable time difference, with data from the control group ranging between 1990 and 2015, while Study 03-133 started enrolling patients in 2004. Changes in standard and supportive care over the time period could also have skewed the results, said the FDA reviewer.

article thumbnail

The Febrile Infant: Incorporating the 2021 American Academy of Pediatrics guidelines

ALiEM - Pharm Pearls

2004 Mar 10;291(10):1261-2. Febrile infants 29-60 days old may be sent home after a negative workup with close follow-up. References: Roberts KB. Young, febrile infants: a 30-year odyssey ends where it started. PMID: 15010450. Biondi EA, Lee B, Ralston SL, et al.

Hospitals 360
article thumbnail

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. He then worked at BCG from 2004 to 2011, where he developed expertise in the energy, engineering, and high-tech sectors.